Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Wellcome Trust | OTHER |
| Department of Health, United Kingdom | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The extent and duration of tissue hypoxia is a major determinant of outcome following major, high-risk surgery and in critical illness. Prompt restoration of tissue oxygenation through resuscitation in all likelihood improves outcomes. There are currently no bedside monitors in clinical practice that track tissue perfusion per se, instead clinicians rely on crude surrogates such as heart rate and blood pressure, urine output, serum lactate of global flow (cardiac output) monitoring.
This is a first-in-man trial of a new device to measure tissue oxygenation in real time in a major, high-risk surgical and critical care cohort. The device consists of an oxygen sensing probe incorporated into a modified urinary catheter, which relies on photoluminescence technology and the quenching properties of oxygen.
Once inserted, the drained bladder collapses round and envelopes the probe which continuously measures tissue oxygenation of the bladder urothelium.
The investigators hope to (i) Establish that tissue oxygenation can be safely monitored using this technology, deployed in this way. (ii) Define a normal range for bladder tissue oxygenation in man as measured using this device. (iii) Compare tissue oxygenation against other markers of perfusion status in current clinical practice and assess its performance at detecting inadequate perfusion against these other modalities. (iv) assess the diagnostic and prognostic capabilities of the tissue oxygenation monitoring at detecting hypo-perfusion and predicting outcome. (v) Further assess the tissue response to an 'oxygen challenge' in identifying occult hypo-perfusion. (vi). Provide pilot work required to inform future, interventional studies where similar patients would be resuscitated to tissue oxygenation targets alongside routine clinical practice.
As above
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High risk surgery | those undergoing elective and emergency, high-risk surgery receiving arterial cannulation and urethral catheterisation as standard |
| |
| Critical Care | Emergency admissions to UCLH critical care unit receiving arterial cannulation and urethral catheterisation as standard |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| WellBeing catheter | Device | Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time to identification of a low bladder tissue PO2 versus time to development of hyperlactatemia (2 mmol/l) | Comparison of bladder tissue PO2 values (normal range to be defined as part of this first-in-man study) against lactate values >2 mmol/l | Up to 7 days |
| Time to identification of a low bladder tissue PO2 versus time to development of hypotension (mean BP <60 mmHg) | Comparison of bladder tissue PO2 values (normal range to be defined as part of this first-in-man study) against mean BP values <60 mmHg | Up to 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Device-Related Adverse Events | Monitoring of direct device-related complications (e.g. bleeding, bladder perforation) | Up to 28 days |
| Identification of future complications in postoperative patients |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
as described above
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mervyn Singer, MB BS | Contact | +44-207-679-6714 | m.singer@ucl.ac.uk | |
| David Brealey, MB BS | Contact | d.brealey@nhs.net |
| Name | Affiliation | Role |
|---|---|---|
| Mervyn Singer, MD | UCL | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCL Hospitals NHS Foundation Trust | Recruiting | London | NW1 | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012769 | Shock |
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
Not provided
Not provided
Not provided
Not provided
Not provided
Low bladder tissue PO2 values identify postoperative complications using POMS-score-defined morbidity at Days 3 and 7
| Up to 7 days |
| D007249 | Inflammation |